Skip to main content
Signal8
Launch Terminal

MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Madrigal Pharmaceuticals, Inc. logo

Madrigal Pharmaceuticals, Inc.

NASDAQ:MDGLHealthcare
-0.31%$430.36
AH$433.06+0.63%vs close
Mkt Cap$9.94B
Float14.91M
O/S23.1M
Vol
$ Vol
RVOL
Inst Own101.9%
SI14.7%
Earnings
Dilution
Madrigal Pharmaceuticals, Inc. logoNASDAQ:MDGL$430.36-0.31%
Phase Distribution
46 lead-sponsored trials·8 active·32 completed
Phase 122
Phase 1/23
Phase 212
Phase 2/31
Phase 36
Phase 41
Not applicable1
(14 more as collaborator)
Status Overview
Recruiting5
Active, not recruiting3
Completed32
Stopped4
Unknown2

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 4
    Recruiting

    Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 Fibrosis

    Rezdiffra, Resmetirom

    MASH - Metabolic Dysfunction-Associated Steatohepatitis

    Enrollment
    150
    Start
    Oct 2026
    Primary Completion
    Nov 2027est.
    Completion
    Nov 2027est.
    NCT07848191
  • Phase 3
    Terminated

    Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma

    Elesclomol (STA-4783), Paclitaxel

    Melanoma

    Enrollment
    630
    Start
    Aug 2007
    Primary Completion
    Jun 2009
    Completion
    Jun 2009
    NCT00522834
  • Phase 3
    Terminated

    A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC

    Docetaxel, Ganetespib

    Non-Small-Cell Lung Adenocarcinoma, Non-small Cell Lung Cancer Stage IIIB +2

    Enrollment
    696
    Start
    Apr 2013
    Primary Completion
    Dec 2015
    Completion
    Dec 2015
    NCT01798485
  • Phase 3
    Active, not recruiting

    A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis

    MGL-3196, Placebo

    NASH - Nonalcoholic Steatohepatitis

    Enrollment
    1,759
    Start
    Mar 2019
    Primary Completion
    Jan 2028est.
    Completion
    Jan 2028est.
    NCT03900429
  • Phase 3
    Completed

    A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients

    Placebo, Resmetirom

    Non-Alcoholic Fatty Liver Disease

    Enrollment
    1,343
    Start
    Dec 2019
    Primary Completion
    Jan 2023
    Completion
    Jan 2023
    NCT04197479
  • Phase 3
    Active, not recruiting

    A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

    Resmetirom

    Non-Alcoholic Fatty Liver Disease

    Enrollment
    810
    Start
    Jul 2021
    Primary Completion
    Mar 2027est.
    Completion
    Apr 2027est.
    NCT04951219
  • Phase 3
    Active, not recruiting

    A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

    Resmetirom, Placebo

    NASH, Cirrhosis, Liver

    Enrollment
    845
    Start
    Aug 2022
    Primary Completion
    Dec 2026est.
    Completion
    Jan 2027est.
    NCT05500222
  • Phase 2/3
    Terminated

    Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer

    Docetaxel, Combination of ganetespib and docetaxel

    Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV +1

    Enrollment
    385
    Start
    May 2011
    Primary Completion
    Apr 2014
    Completion
    Oct 2015
    NCT01348126
  • Phase 2
    Completed

    A Study of STA-4783 in Combination With Weekly Paclitaxel for Treatment of Patients With Soft Tissue Sarcomas

    STA-4783

    Soft Tissue Sarcoma

    Enrollment
    80
    Start
    Jul 2004
    Primary Completion
    -
    Completion
    Oct 2005
    NCT00087997
  • Phase 2
    Completed

    Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease

    STA-5326 mesylate

    Crohn's Disease

    Enrollment
    282
    Start
    Aug 2005
    Primary Completion
    -
    Completion
    -
    NCT00138840
  • Phase 2
    Completed

    Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease

    STA-5326 mesylate

    Crohn's Disease

    Enrollment
    12
    Start
    Nov 2005
    Primary Completion
    -
    Completion
    -
    NCT00234741
  • Phase 2
    Completed

    A Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, Administered to Patients With Rheumatoid Arthritis to Determine Safety, Tolerability, Pharmacokinetic and Synovial Tissue Outcomes

    STA 5326 mesylate, Placebo

    Active, Moderate to Severe Rheumatoid Arthritis

    Enrollment
    35
    Start
    Dec 2005
    Primary Completion
    -
    Completion
    -
    NCT00642629
  • Phase 2
    Completed

    A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)

    STA 9090

    Non Small Cell Lung Cancer

    Enrollment
    113
    Start
    Nov 2009
    Primary Completion
    Jul 2013
    Completion
    Feb 2014
    NCT01031225
  • Phase 2
    Completed

    A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)

    Ganetespib

    Gastrointestinal Stromal Tumor

    Enrollment
    27
    Start
    Jan 2010
    Primary Completion
    Dec 2011
    Completion
    Dec 2011
    NCT01039519
  • Phase 2
    Completed

    A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC)

    Ganetespib

    Non Small Cell Lung Cancer

    Enrollment
    12
    Start
    Apr 2012
    Primary Completion
    Aug 2014
    Completion
    Nov 2014
    NCT01562015
  • Phase 2
    Completed

    An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer

    ganetespib

    Breast Cancer, HER-2 Positive Breast Cancer +2

    Enrollment
    51
    Start
    Jul 2012
    Primary Completion
    Apr 2015
    Completion
    Aug 2015
    NCT01677455
  • Phase 2
    Completed

    Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)

    MGL-3196, Placebo

    Non-alcoholic Steatohepatitis

    Enrollment
    125
    Start
    Oct 2016
    Primary Completion
    Oct 2017
    Completion
    Nov 2021
    NCT02912260
  • Phase 2
    Completed

    Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)

    MGL-3196 (resmetirom), Placebo

    Heterozygous Familial Hypercholesterolemia

    Enrollment
    116
    Start
    Feb 2017
    Primary Completion
    Jan 2018
    Completion
    Jan 2018
    NCT03038022
  • Phase 2
    Recruiting

    Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH

    Resmetirom, Placebo

    MASH - Metabolic Dysfunction-Associated Steatohepatitis

    Enrollment
    120
    Start
    Dec 2025
    Primary Completion
    Aug 2028est.
    Completion
    Mar 2029est.
    NCT07335601
  • Phase 2
    Recruiting

    Study of Resmetirom in Children and Adolescents With MASH

    Resmetirom

    MASH, MASH - Metabolic Dysfunction-Associated Steatohepatitis

    Enrollment
    61
    Start
    Aug 2026
    Primary Completion
    Jul 2029est.
    Completion
    Jul 2029est.
    NCT07763015
  • Phase 1/2
    Completed

    STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma

    STA-4783, Paclitaxel

    Melanoma

    Enrollment
    103
    Start
    May 2004
    Primary Completion
    -
    Completion
    -
    NCT00084214
  • Phase 1/2
    Completed

    STA-5326 in Crohn's Disease Patients

    STA-5326

    Crohn's Disease

    Enrollment
    48
    Start
    Feb 2004
    Primary Completion
    -
    Completion
    Nov 2004
    NCT00088062
  • Phase 1/2
    Completed

    STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)

    Paclitaxel, Carboplatin

    Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer

    Enrollment
    86
    Start
    Mar 2004
    Primary Completion
    -
    Completion
    Mar 2005
    NCT00088088
  • Phase 1
    Completed

    STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematologic Malignancies and Patients With Solid Tumors

    STA-5312

    Hematological Malignancies, Leukemia +2

    Enrollment
    42
    Start
    Feb 2004
    Primary Completion
    -
    Completion
    Dec 2004
    NCT00088101
  • Phase 1
    Completed

    STA-4783 and Paclitaxel for Treatment of Solid Tumors

    STA-4783/paclitaxel

    Neoplasms

    Enrollment
    50
    Start
    Jan 2003
    Primary Completion
    Oct 2004
    Completion
    Oct 2004
    NCT00088114

1-25 of 46

Search ClinicalTrials.gov for “Madrigal Pharmaceuticals”